Condition

Bladder Neoplasms

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 3 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting0

Common interventions3

Lead sponsors shown3

Clinical trials

3 shown

CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician ChoiceNCT02900248 · 2017-10-02

TERMINATED

Combidex USPIO - Ultra-small Superparamagnetic Iron OxideNCT00188695 · 2004-04-01

COMPLETED

Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory MalignanciesNCT00050687 · 2001-06-01

TERMINATED

Common interventions

Gallium maltolateDRUG1 MRI contrast agent Combidex (ferumoxtran-10)PROCEDURE1 Provider determinedOTHER1

Leading sponsors

CureOne 1 Titan Pharmaceuticals 1 University Health Network, Toronto 1

Trial status mix

TERMINATED2

COMPLETED1

Phase mix

PHASE12

PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.